The Difference in the Effects on Microalbuminuria Depending on the Order of GLP-1RA and SGLT2i Therapy in Type 2 Diabetes

被引：0
|
作者：
Ohara, Masaya
Motoyama, Koka
Tamai, Anna
Sakura, Takeshi
Yakushiji, Yosuke
Hosoi, Masayuki
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-545-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
545-P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Stroke, acute myocardial infarction and mortality in type 2 diabetes: a nationwide comparative effectiveness study of GLP-1RA, SGLT2i and DPP-4i treatment
    Hastrup, S.
    Hedegaard, J.
    Andersen, G.
    Osler, M.
    Rungby, J.
    Johnsen, S.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S345 - S346
  • [32] Comparing Cardiovascular Benefits between GLP-1RA and SGLT2i as an Add-On to Metformin among US Adults with Type 2 Diabetes (T2D)
    Deremer, Christina E.
    Guo, Jingchuan
    Vouri, Scott M.
    Haller, Michael J.
    Donahoo, William T.
    Winterstein, Almut G.
    Shao, Hui
    DIABETES, 2021, 70
  • [33] Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: Rationale and design of a randomized controlled trial
    Haff, Nancy
    Horn, Daniel M.
    Bhatkhande, Gauri
    Sung, Meekang
    Colling, Caitlin
    Wood, Wendy
    Robertson, Ted
    Gaposchkin, Daniel
    Simmons, Leigh
    Yang, Judy
    Yeh, James
    Crum, Katherine L.
    Hanken, Kaitlin E.
    Lauffenburger, Julie C.
    Choudhry, Niteesh K.
    AMERICAN HEART JOURNAL, 2025, 285 : 39 - 51
  • [34] Trends in GLP1RA and SGLT2i Use in Ischemic Stroke Patients With Diabetes
    Yanus, Matthew R.
    Saleni, Angela
    Bhavsar, Riya
    Zhang, Tony
    McCane, Charles D.
    Pan, Alan P.
    Vahidy, Farhaan
    Gadhia, Rajan R.
    STROKE, 2024, 55
  • [35] Combined treatment with SGLT2i and GLP1ra compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry
    Garcia Vega, D.
    Cinza-Sanjurjo, S.
    Eiras, S.
    Gonzalez-Juanatey, J. R.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 591 - 591
  • [36] Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes
    Luo, Jing
    Gabriel, Nico
    Korytkowski, Mary
    Hernandez, Inmaculada
    Gellad, Walid F.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 187
  • [37] SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
    Anson, Matthew
    Zhao, Sizheng S.
    Austin, Philip
    Ibarburu, Gema H.
    Malik, Rayaz A.
    Alam, Uazman
    DIABETOLOGIA, 2023, 66 (10) : 1869 - 1881
  • [38] SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
    Matthew Anson
    Sizheng S. Zhao
    Philip Austin
    Gema H. Ibarburu
    Rayaz A. Malik
    Uazman Alam
    Diabetologia, 2023, 66 : 1869 - 1881
  • [39] Risk-Benefit of SGLT2 Inhibitors (SGLT2i) vs. GLP-1 Receptor Agonists (GLP-1RA) in Routine Care of Older Adults
    Patorno, Elisabetta
    Kim, Dae H.
    Pawar, Ajinkya
    Schneeweiss, Sebastian
    Glynn, Robert J.
    Munshi, Medha
    Bessette, Lily G.
    Kim, Seoyoung C.
    DIABETES, 2019, 68
  • [40] Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction Call for Action to the Cardiology Community
    Nelson, Adam J.
    Pagidipati, Neha J.
    Aroda, Vanita R.
    Cavender, Matthew A.
    Green, Jennifer B.
    Lopes, Renato D.
    Al-Khalidi, Hussein
    Gaynor, Tanya
    Kaltenbach, Lisa A.
    Kirk, Julienne K.
    Lingvay, Ildiko
    Magwire, Melissa L.
    O'Brien, Emily C.
    Pak, Jonathan
    Pop-Busui, Rodica
    Richardson, Caroline R.
    Reed, Monica
    Senyucel, Cagri
    Webb, Laura
    McGuire, Darren K.
    Granger, Christopher B.
    CIRCULATION, 2021, 144 (01) : 74 - 84
12345